stockrow
Saturday 7 November 2026
Export GYRE’s income statement to Excel — free account
Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
- Revenue
- +7.75%
- EPS
- −200.0%
- Free cash flow
- −129.9%
Quarter to September 2026, against a year earlier
4.72
0.71
+17.71%
Follow GYRE
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 86.43 | 128.36 |
Piotroski F-Score |
2 | 4 | 4 | — | — | — | 8 | 4 | 5 | 4 |
Altman Z-Score |
(6.50) | (3.81) | 8.65 | — | (1.65) | (13.25) | 26.30 | 25.08 | 23.76 | 16.83 |
P/S ratio |
19.34 | 48.36 | 117.55 | — | 5.78 | 3.82 | 5.21 | 13.80 | 9.74 | 5.41 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 97.97 | 87.15 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(12.82) | (9.29) | 24.45 | — | (5.67) | (26.84) | 9.96 | (2.01) | 5.15 | 8.71 |
P/Operating CF |
(1.55) | (7.79) | (9.82) | — | (5.48) | (1.59) | 13.18 | 466.11 | (373.33) | (112.14) |
Beneish M-Score |
(3.91) | — | — | — | — | — | 9.51 | (6.80) | (1.20) | (2.02) |
P/B ratio |
0.48 | 1.60 | 0.74 | — | 1.59 | 0.68 | 7.72 | 112.28 | 10.46 | 10.59 |
Price to Tangible BV |
0.48 | 1.60 | 0.74 | — | 1.59 | 0.68 | 7.93 | 127.84 | 10.65 | 11.51 |
EV/Sales |
(23.24) | 16.39 | (35.10) | — | 2.24 | (1.85) | 5.02 | 13.56 | 9.53 | 4.66 |
EV/EBITDA |
0.46 | 0.00 | 0.79 | — | 0.00 | 0.16 | 52.04 | 0.00 | 56.80 | 38.79 |
EV/Operating CF |
0.50 | (0.84) | 0.93 | — | (0.85) | 0.16 | 50.36 | 59.40 | (276.90) | 537.99 |
EV/FCF |
0.57 | (0.84) | 0.91 | — | (0.85) | 0.16 | 94.47 | 85.58 | (158.25) | (615.37) |
Quick Ratio |
1.66 | 4.32 | 25.03 | 3.18 | 4.65 | 3.44 | 3.46 | 2.49 | 2.64 | 4.58 |
Current Ratio |
1.71 | 4.48 | 25.83 | 3.32 | 5.03 | 3.63 | 4.06 | 2.85 | 3.32 | 5.60 |
Net Debt/EBITDA |
0.86 | 1.51 | 3.57 | 1.35 | 1.39 | 0.53 | (2.44) | 0.51 | (1.50) | (3.74) |
Debt/Assets |
50.94% | 12.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
1.21 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.03 | 0.00 | 0.00 | 0.22 | 0.10 | 1.46 | 1.13 | 0.87 | 0.80 |
Operating CF/Net income |
1.09 | 0.78 | 0.95 | 0.79 | 0.98 | 0.95 | 4.64 | (0.28) | (0.30) | 0.20 |
Capex/Depreciation |
5.39 | (0.13) | (2.52) | (0.44) | (1.93) | (2.89) | (4.43) | (7.11) | (1.72) | (0.75) |
Interest Coverage |
— | — | — | (26.70) | (102.26) | (2,253.69) | 17.14 | — | — | — |
| (71.35%) | (108.92%) | (39.88%) | (58.61%) | (77.89%) | (150.11%) | 4.06% | (215.71%) | 21.51% | 4.18% | |
| (31.49%) | (65.75%) | (36.56%) | (49.38%) | (58.16%) | (116.85%) | 3.28% | (92.34%) | 9.99% | 3.45% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 12.23% | (93.45%) | 14.08% | 7.99% |
Return on Tangible Assets |
(105.91%) | (83.25%) | (25.13%) | (81.78%) | (77.95%) | (229.70%) | 4.18% | (153.70%) | 17.48% | 4.67% |
Average Days of Receivables |
28.36 | 0.00 | 0.00 | 0.00 | 57.73 | 90.43 | 61.15 | 52.92 | 85.52 | 98.02 |
Research and Development Expense of Revenue |
2,895.99% | 1,261.98% | 357,900.00% | 0.00% | 252.89% | 938.80% | 16.31% | 85.40% | 11.37% | 11.75% |
Selling, General and Administrative Expense of Revenue |
2,321.30% | 981.63% | 205,900.00% | 0.00% | 77.24% | 258.42% | 70.00% | 66.83% | 69.61% | 73.75% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.04 |
Share Based Compensation of Revenue |
159.15% | 84.77% | 43,433.33% | 0.00% | 17.31% | 46.40% | 13.07% | 6.42% | 0.79% | 6.14% |
Graham Net Nets |
2.01 | 0.62 | 1.34 | — | 0.58 | 1.32 | 0.07 | 0.01 | 0.04 | 0.19 |
Graham Number |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 1.91 | 0.91 |
Earnings Yield |
(218.48%) | (65.38%) | (33.57%) | — | (44.83%) | (313.85%) | (44.44%) | (10.01%) | 1.16% | 0.78% |
Free Cash Flow Yield |
(212.26%) | (40.55%) | (32.68%) | — | (45.69%) | (302.04%) | 1.02% | 1.15% | (0.62%) | (0.14%) |
Revenue per Share |
7.67 | 4.46 | 0.01 | 0.00 | 16.38 | 3.59 | 1.61 | 1.72 | 1.24 | 1.30 |
Operating CF per Share |
(355.23) | (87.30) | (38.17) | (54.47) | (43.03) | (40.98) | 0.17 | 0.39 | (0.04) | 0.01 |
Capex per Share |
40.31 | (0.10) | (0.50) | (0.08) | (0.21) | (0.41) | (0.08) | (0.12) | (0.03) | (0.02) |
Free Cash Flow per Share |
(314.92) | (87.40) | (38.68) | (54.55) | (43.24) | (41.39) | 0.09 | 0.27 | (0.07) | (0.01) |
Cash per Share |
702.54 | 165.39 | 160.66 | 96.00 | 62.03 | 22.92 | 0.40 | 0.51 | 0.31 | 0.59 |
Shareholders Equity per Share |
309.06 | 134.74 | 160.35 | 85.35 | 59.47 | 20.10 | 1.14 | 1.19 | 1.16 | 1.59 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
309.06 | 134.74 | 160.35 | 85.35 | 59.47 | 20.10 | 1.14 | 1.19 | 1.16 | 1.59 |
Free Cash Flow |
(16.38) | (19.96) | (28.93) | (43.68) | (55.31) | (84.59) | 5.68 | 17.97 | (6.37) | (0.88) |
Working Capital |
15.56 | 30.37 | 119.19 | 67.17 | 71.71 | 37.31 | 37.41 | 37.17 | 45.27 | 84.08 |
Capital Expenditures |
2.10 | (0.02) | (0.38) | (0.06) | (0.27) | (0.84) | (5.00) | (7.92) | (2.73) | (1.89) |
Net Current Asset Value |
15.50 | 30.37 | 119.02 | 65.85 | 70.73 | 36.90 | 37.12 | 19.16 | 37.78 | 78.52 |
EV/EBIT |
0.45 | 0.00 | 0.78 | — | 0.00 | 0.15 | 58.43 | 0.00 | 62.38 | 47.30 |
Capex to Sales |
(5.25) | 0.02 | 62.67 | 0.00 | 0.01 | 0.11 | 0.05 | 0.07 | 0.03 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 60.60 | 0.00 | 63.70 | 54.91 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.88 | 0.63 | 0.39 | 0.48 | 0.32 | 0.30 | 0.06 | 0.05 | 0.07 | 0.11 |
Cash ROIC |
(22.74%) | (27.11%) | (12.05%) | (30.08%) | (35.59%) | (96.20%) | 5.83% | 16.05% | (5.09%) | (0.45%) |
Accounts Receivable Turnover |
1.53 | 0.00 | 0.00 | 0.00 | 2.29 | 2.86 | 10.79 | 6.76 | 5.13 | 4.16 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.05 | 1.79 | 1.20 | 1.47 | 19.44 | 16.78 | 46.69 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.89 | 0.73 | 0.66 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 10,697.50 | 236.26 | 317.47 | 9.29 | 27.95 | 10.15 | 8.36 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 466.21 | 337.05 | 595.52 | 685.45 |
Average Receivables |
0.26 | — | — | 7.52 | 9.16 | 2.57 | 9.48 | 16.79 | 20.62 | 28.04 |
Average Payables |
0.89 | 0.79 | 1.00 | 2.76 | 5.11 | 6.18 | 3.27 | 0.24 | 0.23 | 0.12 |
Average Inventory |
— | — | — | — | — | — | — | 5.20 | 5.31 | 8.25 |
Average Assets |
53.81 | 38.80 | 82.22 | 111.74 | 96.70 | 75.25 | 70.21 | 100.65 | 120.97 | 145.77 |
Average Common Equity |
23.75 | 23.42 | 75.36 | 94.14 | 72.20 | 58.58 | 56.65 | 43.08 | 56.18 | 120.34 |
Columns are period end dates · fundamentals updated 6 Nov 2026